CCNE1基因表达状态在卵巢癌中的预后价值
|
摘要
目的:探讨CCNE1基因表达状态对卵巢癌总生存结果的影响及预后价值。方法:利用The Kaplan Meier plotter数据库中的卵巢癌患者生存资料及CCNE1基因表达资料,分析不同CCNE1基因表达状态下卵巢癌的总生存差异,探索CCNE1基因表达的预后价值。结果:共检出1 656例卵巢癌患者用于最终的生存分析,根据CCNE1基因表达状态,分为低表达组(1 171例)和高表达组(485例),低表达组卵巢癌中位总生存时间为48.0个月,高表达组为37.4个月,差异有统计学意义(P=0.001),风险比HR=1.26,95%CI(1.10,1.44)。结论:CCNE1基因高表达降低卵巢癌总生存,是不良预后因子。
Objective:To investigate the effect and prognostic value of CCNE1 gene expression status on the overall survival of ovarian cancer.Method:The survival data of ovarian cancer patients and CCNE1 gene expression data in The Kaplan Meier plotter database were used to analyze the difference in the overall survival of ovarian cancer with different CCNE1 gene expression status,and to explore the prognostic value of CCNE1 gene expression.Result:A total of1 656 ovarian cancer patients were detected for the final survival analysis.According to CCNE1 gene expression status,patients were divided into two groups,the low-expression group(1 171 cases) and high expression group(485 cases).Median overall survival time for low-expression group ovarian cancer was 48.0 months,while for the high expression group was 37.4 months,the difference was statistically significant(P=0.001),HR=1.26,95%CI(1.10,1.44).Conclusion:The high expression of CCNE1 gene reduces the overall survival of ovarian cancer,which is a poor prognostic factor.
Objective:To investigate the effect and prognostic value of CCNE1 gene expression status on the overall survival of ovarian cancer.Method:The survival data of ovarian cancer patients and CCNE1 gene expression data in The Kaplan Meier plotter database were used to analyze the difference in the overall survival of ovarian cancer with different CCNE1 gene expression status,and to explore the prognostic value of CCNE1 gene expression.Result:A total of1 656 ovarian cancer patients were detected for the final survival analysis.According to CCNE1 gene expression status,patients were divided into two groups,the low-expression group(1 171 cases) and high expression group(485 cases).Median overall survival time for low-expression group ovarian cancer was 48.0 months,while for the high expression group was 37.4 months,the difference was statistically significant(P=0.001),HR=1.26,95%CI(1.10,1.44).Conclusion:The high expression of CCNE1 gene reduces the overall survival of ovarian cancer,which is a poor prognostic factor.
引文
[1]Torre L A,Bray F,Siegel R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2]Siegel R L,Miller K D,Jemal A.Cancer Statistics,2017[J].CA Cancer JClin,2017,67(1):7-30.
[3]Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[4]Gyorffy B,Lanczky A,Szallasi Z.Implementing an online tool for genomewide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients[J].Endocr Relat Cancer,2012,19(2):197-208.
[5]Etemadmoghadam D,Au-Yeung G,Wall M,et al.Resistance to CDK2inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer[J].Clin Cancer Res,2013,19(21):5960-5971.
[6]Noske A,Henricksen L A,Lafleur B,et al.Characterization of the19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes[J].Exp Mol Pathol,2015,98(1):47-54.
[7]Kuhn E,Bahadirli-Talbott A,Shih Ie M.Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma[J].Mod Pathol,2014,27(7):1014-1019.
[8]Amininia S,Hashemi M,Ebrahimi M,et al.Association between CCNE1polymorphisms and the risk of breast cancer in a sample of southeast Iranian population[J].Med Oncol,2014,31(10):189.
[9]Ooi A,Oyama T,Nakamura R,et al.Gene amplification of CCNE1,CCND1,and CDK6 in gastric cancers detected by multiplex ligationdependent probe amplification and fluorescence in situ hybridization[J].Hum Pathol,2017,61(1):58-67.
[10]Nakayama N,Nakayama K,Shamima Y,et al.Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer[J].Cancer,2010,116(11):2621-2634.
[11]Pils D,Bachmayr-Heyda A,Auer K,et al.Cyclin E1(CCNE1)as independent positive prognostic factor in advanced stage serous ovarian cancer patients-a study of the OVCAD consortium[J].Eur J Cancer,2014,50(1):99-110.
[12]Zhao H,Wang J,Zhang Y,et al.Prognostic Values of CCNE1Amplification and Overexpression in Cancer Patients:A Systematic Review and Meta-analysis[J].J Cancer,2018,9(13):2397-2407.
[2]Siegel R L,Miller K D,Jemal A.Cancer Statistics,2017[J].CA Cancer JClin,2017,67(1):7-30.
[3]Chen W,Zheng R,Baade P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[4]Gyorffy B,Lanczky A,Szallasi Z.Implementing an online tool for genomewide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients[J].Endocr Relat Cancer,2012,19(2):197-208.
[5]Etemadmoghadam D,Au-Yeung G,Wall M,et al.Resistance to CDK2inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer[J].Clin Cancer Res,2013,19(21):5960-5971.
[6]Noske A,Henricksen L A,Lafleur B,et al.Characterization of the19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes[J].Exp Mol Pathol,2015,98(1):47-54.
[7]Kuhn E,Bahadirli-Talbott A,Shih Ie M.Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma[J].Mod Pathol,2014,27(7):1014-1019.
[8]Amininia S,Hashemi M,Ebrahimi M,et al.Association between CCNE1polymorphisms and the risk of breast cancer in a sample of southeast Iranian population[J].Med Oncol,2014,31(10):189.
[9]Ooi A,Oyama T,Nakamura R,et al.Gene amplification of CCNE1,CCND1,and CDK6 in gastric cancers detected by multiplex ligationdependent probe amplification and fluorescence in situ hybridization[J].Hum Pathol,2017,61(1):58-67.
[10]Nakayama N,Nakayama K,Shamima Y,et al.Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer[J].Cancer,2010,116(11):2621-2634.
[11]Pils D,Bachmayr-Heyda A,Auer K,et al.Cyclin E1(CCNE1)as independent positive prognostic factor in advanced stage serous ovarian cancer patients-a study of the OVCAD consortium[J].Eur J Cancer,2014,50(1):99-110.
[12]Zhao H,Wang J,Zhang Y,et al.Prognostic Values of CCNE1Amplification and Overexpression in Cancer Patients:A Systematic Review and Meta-analysis[J].J Cancer,2018,9(13):2397-2407.